Detail akcie Briacell Therap Rg online

Business Summary: BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Financial Summary: BRIEF: For the three months ended 31 October 2025, Briacell Therapeutics Corp revenues was not reported. Net loss increased 41% to $8.2M. Higher net loss reflects Research and development expenses increase of 82% to $6.7M (expense), General and administrative expenses increase of 10% to $1.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$32.67 to -$4.35.